Aspergillus belongs to the ascomycete moulds, which together with penicillium form the family of Aspergillaceae. These filamentous fungi are ubiquitous and are commonly in humid areas, damp soil or agricultural environments, on grain, cereal, mouldy flour, and organic decaying or decomposing matter. Aspergillus grow by budding or branching. The former or conidium, 1–3 µm in diameter, are carried by air and easily inhaled in the lungs. The branching hyphae are 2–5 µm in diameter, split dichotomously at a 45° angle, and are best recognized by methanamine silver stain.

Of more than 350 species that belong to the genus aspergillus, only Aspergillus fumigatus and A. niger produce disease in humans with any frequency. Under certain conditions, however, A. clavatus, A. glaucus, A. flavus, A. versicolor, A. nidulans and A. oryzae can cause infection in humans and animals.

Humans have a remarkable capacity to eliminate aspergillus with the help of alveolar macrophages which phagocytose and destroy the inhaled spores. Thus, aspergillus rarely invades the immunocompetent host. Nevertheless, aspergillus can cause a variety of clinical syndromes ranging from mild, transient asthma to fatal, disseminated disease, particularly in the immunosuppressed host. Aspergillus-related pulmonary disorders may be classified into four clinical categories depending on whether the host is atopic, nonatopic or immunosuppressed (table 1). Some of these clinical entities are well defined and common; others are unusual but recognized; and, still others rare and controversial [1–6]. The key points in the pathogenesis, imm-une response, diagnosis and treatment of each syndrome are summarized (tables 2 and 3).

**Allergic or hypersensitive reactions**

Allergic asthma

Storm van Leeuwen [1] was the first to attribute a role to A. fumigatus in the causation of asthma in Leyden. Aspergillus is responsible for asthma to the same extent as Alternaria, Penicillium, and other fungi. The illness seems to be more common in the UK, 10–20% of cases with respiratory problems, and in Holland about 15%. Since aspergillus grows in humid dwellings on wood and old furniture, on dusty belongings, and on indoor plants, asthma episodes are clinically due to domestic exposure in the USA, such episodes are more common between October and...
February, when aspergillus spore count is high, than at other times of the year. Although humidity, rain and wind play an important role in disseminating the spores, the peak levels are greater during fair weather that follows a period of rain. At any rate, CHARPIN et al. demonstrated that the spores of aspergillus are present in all seasons.

An intracutaneous test using aspergillus antigen produces an immediate wheal and flare reaction in asthma patients who are allergic to the mould. Furthermore, inhalation of the antigen causes rapid bronchospasm. In making the diagnosis, however, the physician should be cautious, because 30–40% of patients with non-aspergillus induced asthma may also have a positive reaction to Aspergillus skin test. Precipitating (immunoglobulin (Ig)G) antibodies are usually absent in such patients. Treatment includes β-adrenergic agonists, as needed, to relieve symptoms. Cromolyn or nedocromil sodium can prevent symptoms if the drug is administered before anticipated exposure to the allergen.

### Table 2. Pulmonary aspergillosis: immunological and diagnostic tests

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Type I reaction</th>
<th>Type III reaction</th>
<th>Type IV reaction</th>
<th>Other diagnostic tests</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Immediate cutaneous hypersensitivity</td>
<td>Serum IgE</td>
<td>Delayed (Arthus) skin reaction</td>
<td>Precipitating antibodies</td>
</tr>
<tr>
<td>Allergic asthma</td>
<td>Positive</td>
<td>Increased</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Allergic bronchopulmonary aspergillosis</td>
<td>Positive</td>
<td>Markedly increased</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Extrinsic allergic alveolitis (malt-worker's lung)</td>
<td>Usually positive</td>
<td>Usually normal</td>
<td>Present</td>
<td>Present</td>
</tr>
<tr>
<td>Bronchocentric granulomatosis</td>
<td>May be positive</td>
<td>May be increased</td>
<td>May be present</td>
<td>May be present</td>
</tr>
<tr>
<td>Pneumonia, lung abscess, bronchitis, infarction</td>
<td>May be positive</td>
<td>Normal</td>
<td>Absent*</td>
<td>Absent*</td>
</tr>
<tr>
<td>Multiple cavities, pleural effusion</td>
<td>Usually negative*</td>
<td>Normal</td>
<td>Absent*</td>
<td>May be present</td>
</tr>
<tr>
<td>Chronic necrotizing pulmonary aspergillosis</td>
<td>May be positive</td>
<td>Normal</td>
<td>Present</td>
<td>Very high</td>
</tr>
</tbody>
</table>

*: opinions expressed in the medical literature are divided regarding these conclusions, but many of these tests will be positive if the highest quality antigen is used and a research laboratory performs the tests. IgE: immunoglobulin E; CT: computed tomography.

### Allergic bronchopulmonary aspergillosis

HINSON et al. [7] provided the first descriptions of allergic bronchopulmonary aspergillosis (ABPA), followed by PUPS et al. [3], CAMPBELL and CLAYTON [8] reported 87 cases, FRANKLAND and DAVIS [9] 36 cases, HENDERSON [10] 32 cases, SIMON [11] 111 cases and EDGE et al. [12] 12 cases, all in the UK. In the USA, this disorder was thought to be rare. However, SWAB et al. [13] described 36 cases under the term "mucoid impaction" in which aspergillus aetiology was almost certain. The incidence of ABPA varies from 6–20% of all patients with asthma [14]. It occurs with equal frequency in both sexes. Most patients are under age 35 yrs at the time of diagnosis. In patients with cystic fibrosis, the prevalence of ABPA is 0.5–11%.

The disease manifests itself with low-grade fever, cough, wheezing, golden, brown mucus plugs, and progressive shortness of breath. Pleuritic chest pain and haemoptysis are frequent. PATTERSON and coworkers [15–17] have proposed five stages of ABPA. However, these stages are not

### Table 3. Pulmonary aspergillosis: clinical syndromes and treatment

<table>
<thead>
<tr>
<th>Syndromes</th>
<th>Immunological mechanism</th>
<th>Host</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Atopic</td>
<td>Immuno-suppressed</td>
</tr>
<tr>
<td>Allergic asthma</td>
<td>Hypersensitivity (type I)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Allergic bronchopulmonary aspergillosis</td>
<td>Hypersensitivity (types I and III)</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Extrinsic allergic alveolitis (malt-worker’s lung)</td>
<td>Hypersensitivity (types III and IV)</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bronchocentric granulomatosis</td>
<td>Hypersensitivity (types III and IV)</td>
<td>Some</td>
<td>No</td>
</tr>
<tr>
<td>Pneumonia, lung abscess, bronchitis, infarction</td>
<td>Invasive (infective) localized disease</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Multiple cavities, pleural effusion</td>
<td>Invasive (infective) disseminated disease</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Chronic necrotizing pulmonary aspergillosis</td>
<td>Invasive, chronic, localized disease</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Aspergilloma</td>
<td>Saprophytic colonization</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Mycotoxicosis</td>
<td>Chemical, pneumonitis</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>
Clinical features

Serum IgE
Chest radiograph
IgE-Af

Table 4 — Allergic bronchopulmonary aspergillosis: clinical stages

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical features</th>
<th>Chest radiograph</th>
<th>Serum IgE</th>
<th>Peripheral eosinophilia</th>
<th>Precipitating antibody to Af</th>
</tr>
</thead>
<tbody>
<tr>
<td>I Acute</td>
<td>Cough, wheezing, fever, sputum plugs may be present</td>
<td>Transient lung infiltrates</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>II Remission</td>
<td>Usually no symptoms</td>
<td>No radiographic infiltrate</td>
<td>+</td>
<td>+/-</td>
<td>-</td>
</tr>
<tr>
<td>III Exacerbation</td>
<td>Fever, cough, and wheezing may be absent</td>
<td>Pulmonary infiltrates</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>IV Corticosteroid dependent asthma</td>
<td>Persistent disabling wheezing</td>
<td>Pulmonary infiltrate usually absent</td>
<td>++</td>
<td>+/-</td>
<td>+/-</td>
</tr>
<tr>
<td>V Fibrotic</td>
<td>Dyspnoea, wheezing, clubbing of the fingers, cyanosis, chronic sputum production</td>
<td>Extensive fibrosis/honeycombing, segmental/lobar atelectasis</td>
<td>+</td>
<td>+/-</td>
<td>-</td>
</tr>
</tbody>
</table>

IgE: immunoglobulin E; Af: Aspergillus fumigatus; IgE-Af: specific IgE direct against Af. +: presence of; -: absence of.

necessarily phases of the disease, and there is not always an inexorable progression of the disease from stage I to the end stage fibrosis of stage V (table 4).

Physical examination may reveal a prolonged expiratory phase and diffuse rhonchi in almost all patients; whereas, cracks or crepitations are present only in those with pulmonary infiltrates.

Eosinophilia is almost always present with absolute counts over 500 cells·mm\(^{-3}\) and usually over 1,000 cells·mm\(^{-3}\); however, ABPA has been identified in patients without elevated eosinophil counts. Sputum eosinophils are often present. Levels of total IgE and specific IgE for aspergillus species (IgE-Af) are increased. IgE-Af determination is useful in excluding mould-sensitive asthmatics without ABPA who either have very low or absent isotypic antibodies to aspergillus. Serum precipitating antibodies or precipitins (IgG) are positive in >90% of cases, but one should not exclude ABPA in a patient with consistent clinical and radiographic findings if precipitating antibody to aspergillus (IgG-Af) is absent. IgE levels are the best indicator of disease activity and should be monitored regularly (fig. 1). However, occasionally, the total serum IgE level may remain elevated in a patient who has otherwise responded to prednisone. In bronchoalveolar lavage fluid, increased levels of IgE-Af are found, reflecting the role of the lung as a specific immunological organ. This observation, however, provides no diagnostic or therapeutic assistance.

Skin test reactivity to aspergillus antigen manifests immediately, IgE-dependent as well as late (4–8 h) reactions. Positive reactions may occur in patients with asthma, aspergillosis, and other chronic pulmonary diseases.

Chest radiographs commonly reveal transient, patchy infiltrates and/or lobar collapse and/or consolidation. Characteristically, these infiltrates favour the upper lung fields. Mucus plugging may cause segmental, lobar or total collapse of the lung. "Tram line", "gloved finger", and "ring" shadows reflect inflammation, thickening and dilation of the bronchial tubes (fig. 2a and b). Bronchiectasis, when it appears, is typically central in location and involves the proximal airways (fig. 3). In the advanced stages, loss of volume of the upper lobes and extensive honeycombing dominate the picture. High resolution computed tomography (CT) scanning is the best way of demonstrating bronchial and pulmonary effects of ABPA [18].

The pathogenesis of ABPA involves the inhalation, trapping, and subsequent germination of aspergillus spores in viscous secretions in the airways of atopic individuals, as well as cystic fibrosis patients. The host response with production of IgE and IgG sets in motion a series of antibody-antigen reactions that result in eosinophilic infiltration and bronchial wall damage. It is the immune complex injury that produces bronchiectasis. The presence of IgE is essential to enhance the tissue-damaging effect of immune complexes. The presence of activated epithelial cells and the exposure of the basement membrane that occurs in asthma, together with oxidant stress, may facilitate the colonization of the asthmatic lung by A. fumigatus [19, 20].

Diagnosis of ABPA requires immunological and radiological confirmation in an appropriate clinical setting. Ricketts et al. [21] have proposed a sequential approach to evaluating patients suspected of having ABPA. First begin with skin tests (the prick test), and if necessary, an intra-
dermal test using Aspergillus antigen. The immediate reaction appears in a few minutes and lasts 1–2 h, and the late reaction appears after 4–5 h and lasts for 24–36 h. Only the latter reaction is inhibited by corticosteroids. Negative skin tests exclude ABPA. On the other hand, positive results lead to the prompt ordering of serological tests including total serum IgE, radioallergosorbent test (RAST) IgE-Af, and IgG [22, 23].

The most effective treatment of ABPA is with corticosteroids [24]. Prednisone is usually given as a single oral dose of 0.5 mg·kg⁻¹·day⁻¹ for 2 weeks. The same dose is then given on alternate days for 2–3 months and then tapered to the lowest dose needed to control symptoms. Corticosteroids control eosinophilia, decrease lung infiltrates, sputum production, and total IgE level. The role of antifungal drugs is not yet established but there are several reports that describe the beneficial effects of itraconazole in ABPA [25–27].

ABPA and cystic fibrosis

Aspergillus species are recovered from ~10% of cystic fibrosis patients. The recovery rates increase with age [25–27]. The clinical significance of the fungus in these patients varies. Many patients are asymptomatic with colonized aspergillus. However, ABPA may complicate cystic fibrosis. The diagnosis then requires clinical and immunological confirmation, not simply isolation of the fungus. Invasive aspergillosis is not common in cystic fibrosis patients.

Extrinsic allergic alveolitis

In 1928, Pasteur and Girod [28] described five workers in a distillery who had inhaled massive amounts of A. fumigatus or A. clavatus. Several hours afterwards, dyspnoea appeared with fever, cough, and crepitations on auscultation. Serum-precipitating antibodies were present in three patients. The skin test produced a delayed positive reaction. Riddle et al. [29] reported a 42-yr old brewery worker with interstitial disease due to A. clavatus in which the clinical and immunological findings were similar to those of farmer's lung disease. Ruddy et al. [30] reported a case of extrinsic allergic alveolitis (EAA) due to A. versicolor in a 43-yr old female, who was exposed to handling mouldy straw. The EAA caused by aspergillus species is also called malt-worker's lung. It occurs mainly in nonatopic individuals who work in the whiskey and beer-brewing industries, where germinating barley is contaminated by A. fumigatus or A. clavatus. After initial exposure, there is a latent period of variable duration during which appropriate precipitating antibodies are formed. There are four modes of presentation: 1) acute episodes of fever, cough, dyspnoea, and tightness of the chest occurs in about one third of the patients; 2) progressive dyspnoea seen in ~50% of patients; 3) ~10% present with asthma-like picture (these patients are usually atopic); and 4) a mixed presentation in the remaining 10% of patients [5].

Physical examination in acute stages may reveal cyanosis and tachycardia. Crepitations are present; wheezing is usually absent. In advanced cases, there may be features of right-sided heart failure.

Chest radiographs typically show diffuse, fine nodular infiltration or patchy densities. In the chronic stage,
reticulo-interstitial pattern and honeycombing may be seen. A lung biopsy specimen in acute stages may reveal granulomatous reaction with lymphocytic infiltration. Fibrosis and cyst-formation occur in chronic disease.

Lung function studies reveal a restrictive ventilatory defect caused by reduced lung compliance. Vital capacity, forced expiratory volume in one second (FEV₁) and diffusing capacity are decreased. Airways obstruction is present, particularly in atopic patients. Corticosteroids are effective for controlling symptoms in acute stages. However, exposure to the aspergillus antigen needs to be avoided in order to prevent recurrence and progression to pulmonary fibrosis.

### Bronchocentric granulomatosis

Although bronchocentric granulomatosis (BG) is a well-defined pathological entity, the clinical diagnosis is often difficult (fig. 4) [31, 32]. BG occurs both in atopic and nonatopic individuals. The atopic patients are generally younger and have a history of asthma. Eosinophilia is present and mucus plugs contain fungal hyphae. The nonatopic individuals constitute a much more heterogeneous group. Immunological mechanisms causing BG are not clearly understood, but the basic abnormality seems to be a hypersensitivity to fungal organisms. Serum precipitin antibodies (IgG) are present in ~40% of atopic patients with BG. Corticosteroids are useful in treating patients with BG who have asthma. The prognosis is not favourable in nonatopic patients, but the information available is limited. One patient with bronchocentric granulomatosis developed severe acute respiratory distress syndrome (ARDS) with peripheral blood eosinophilia. The patient was intubated and treated with high-dose corticosteroid therapy. The illness subsided and showed no recurrence during the 20-yr follow-up [33].

### Invasive (disseminated) aspergillosis

Invasive pulmonary aspergillosis is characterized by proliferation of fungal mycelia in the pulmonary parenchyma. Invasion of the pulmonary vasculature may result in haemorrhagic infarction. Invasive fungal infection can remain dormant for some time, and then produce septic shock precipitously [34]. Factors which predispose to the development of invasive aspergillosis are neutropenia, leukaemia, carcinoma, immunosuppression with corticosteroids or immunosuppressive agents including cyclosporine, bone marrow or solid organ transplants, and chronic granulomatous disease of childhood. Therefore, a high index of suspicion should be maintained in such patients. Patients with human immunodeficiency virus (HIV) are not at a high risk unless other factors are present. A comparison of aspergillosis in HIV-positive and HIV-negative patients was carried out by ABERDO-HARRIS et al. [35]. In both groups, tuberculosis and sarcoidosis were significant risk factors. In HIV-positive patients, prior Pneumocystis carinii pneumonia (PCP) also seemed to be a risk factor as 3 of the 10 HIV infected patients with aspergillosis had prior episodes of PCP. Invasive aspergillosis has been reported in HIV patients with CD4 cell counts <500 cells·mL⁻¹ [36, 37]. Because neutrophils and other phagocytic cells are the principal defence against aspergillus, profound neutropenia (<1,000 cells·mm⁻³) that persists for >3 weeks is the most significant risk factor. Macrophages are the first line of defence; they kill conidia. The second line of defence consists of neutrophils, which dispose of mycelia. Neither humoral antibodies nor T-cell-mediated immunity play a significant protective role against the fungus [38]. Invasive aspergillosis is rare in normal healthy people and less than 20 such cases have been described. In immunocompetent hosts marijuana smoking and broad spectrum antibiotics can contribute to invasive aspergillosis [39, 40]. The typical victim of invasive aspergillosis is a neutropenic (<1,000 cells·mm⁻³) individual who is receiving cancer chemotherapy. The patients have persistent fever for which they have either received, or are receiving, multiple antibiotics. Fever may be associated with nasal and sinus congestion, chest pain, cough, dyspnoea, and either blood streaking of the sputum or frank haemoptysis. The following forms of invasive aspergillosis often occur together, but they may also be seen independently.

---

**Fig. 4.** – Bronchocentric granulomatosis: a) granulomatous replacement of the bronchiolar mucosa with occlusion of the lumen; b) destruction of the bronchial wall is evidenced by the giant cell reaction with damaged multilaminated elastic laminae. (Internal scale bars=25 µm.)


Aspergillus pneumonia

The clinical picture resembles any acute bacterial or fungal pneumonia. Initially chest radiographs show only a patchy infiltrate or pneumonitis that may progress to dense consolidation involving one or both lungs [41]. Despite such extensive disease, isolation of aspergillus from sputum samples has been possible in less than half the cases [42–44].

Angioinvasive aspergillosis

This spreads by vascular dissemination. It causes thrombosis and necrosis. The symptoms are intense pleuritic chest pain, sudden dyspnoea, tachycardia and haemoptysis. In approximately one third of patients, the chest radiographs are normal if they are obtained on the day of onset of symptoms. However, if obtained later, the chest radiograph may show a triangular or oval infiltrate with or without pleural effusion. CT scans of the chest may reveal a round or triangular mass with a characteristic "halo". Pathologically, these lesions represent well-circumscribed nodules with a pale yellow centre of coagulative necrosis surrounded by a haemorrhagic periphery [41, 45].

Aspergillus bronchitis/tracheobronchitis

This is a localized form of airway disease characterized by ulcers and membrane formation. Aspergillus hyphae invade the airways and form plugs consisting of mycelia, inflammatory cells, and necrotic debris. These plugs along with the membranes produce airway obstruction resulting in wheezing and dyspnoea. Approximately 10% of patients who have invasive aspergillus develop tracheobronchitis either alone or with pneumonia. A new antifungal drug terbinafin has been successfully used to treat aspergillus bronchitis in a lung transplant recipient [46]. Aspergillus sinusitis can occur in patients with HIV infection [47].

Pleural effusion or empyema

This is a rare manifestation of invasive aspergillosis.

Diagnosis of invasive aspergillosis

The clinical course of invasive aspergillosis is often fulminating and fatal. In many instances this is traceable to a delay in the diagnosis. Such delays are partly related to the fact that the diagnosis is not considered (especially in immunocompromised hosts) partly because the sputum smear or culture lacks sensitivity and specificity in establishing the diagnosis. To avoid the diagnostic pitfalls the clinician must maintain a high index of suspicion for invasive aspergillosis: 1) invasive aspergillosis should always be included in the differential diagnosis of fever, pulmonary infiltration, cavity formation or pleural effusion in an immunocompromised host; 2) repeatedly positive sputum cultures for aspergillus in a susceptible individual should always point towards this diagnosis; and 3) in a granulocytic patient with acute leukaemia a single isolation of aspergillus from sputum; bronchial washing or brushing may be highly significant.

Definite diagnosis, however, requires the demonstration of mycelia, morphologically consistent with aspergillus, invading lung parenchyma in addition to a positive fungal culture. These are often not considered practical requirements in patients with acute leukaemia or a recent bone marrow or solid organ transplant. Empirical treatment should never be withheld in a neutropenic patient in whom invasive aspergillosis is considered.

Aspergillus from sputum samples in patients with invasive pulmonary aspergillosis can be isolated in approximately half of the cases, but it usually lags behind the clinical onset by a week [42–44]. Similarly, the finding of aspergillus in surveillance cultures lacks sensitivity. Bronchoscopy has an overall yield of approximately 50% for recovery of aspergillus. HARRAH and DONNER [48] analyzed 82 lower respiratory tract cultures for aspergillus species in 80 patients at risk for invasive disease. Definite or probable invasive pulmonary aspergillosis was diagnosed in 72% of episodes from patients with haematological malignancy, granulocytopenia or bone marrow transplants; in 58% of those with solid tumours or receiving cortico-steroids; and in 14% with HIV. Thus, recovery of aspergillus from the lower respiratory tract in susceptible individuals constitutes presumptive evidence of fungal invasion [48].

Counter immunoelectrophoresis, immunofluorescence and complement fixation tests are used to detect aspergillus antibodies. However, these tests, as well as radioimmune assays, depend on a normal host immune response - often absent in immunosuppressed patients. A more recent technique based on detecting the circulating galactomannan antigen appears to be promising; but further studies are needed before the test becomes available for general use [49–52].

Similarly, a polymerase chain reaction to detect aspergillus species deoxyribonucleic acid (DNA) in bronchoalveolar lavage fluid is under study [53].

Thus, in most cases of immunosuppressed patients, serological monitoring is insensitive. On the other hand, in the post lung transplant patients, a situation similar to aspergillosis patients exists [54]. TOMEE et al. [55] studied four patients with postlung transplant A. Fumigatus infection. Increasing specific IgG antibody levels paralleled the cytological or microbiological identification and the lung function impairment. Successful treatment resulted in a decrease in the antibody level. These observations require confirmation.

Radiographic findings in patients with invasive aspergillosis include solitary and multiple nodules. CT changes are helpful in detecting early changes that are not present on chest radiographs. Bronchoscopy and/or high resolution CT were performed in a study of 33 patients [34]. The sensitivity of bronchoalveolar lavage (BAL) fluid and washings were 33% and 50% respectively. CT signs of fungal infection were found in 16 (84%) of 19 episodes. More frequent use of bronchoscopy and CT leads to earlier institution of antifungal therapy, resulting in improved survival [56]. Fibreoptic bronchoscopy and bronchial biopsy are safe procedures if performed in patients with normal coagulation studies and platelet counts >50,000/mm³. When fibreoptic bronchial biopsy is negative, and the clinical
Chronic necrotizing pulmonary aspergillosis

Chronic necrotizing pulmonary aspergillosis (CNPA) is an indolent, cavitating lesion that occurs due to localized invasion of the lung tissue by aspergillus. In a review of 22 cases, BURKE et al. [72] found these patients to usually be middle-aged with evidence of generalized immunosuppression in the form of diabetes mellitus, malnutrition, corticosteroid or radiation therapy, and collagen vascular diseases. Fever, cough, and expectoration was always present. Chest radiographs showed a patchy infiltrate with a cavity. In many cases such a lesion can be mistakenly diagnosed as tuberculosis, histoplasmosis, coccidiodomycosis, anaerobic pneumonia, or vasculitis. Diagnosis is established by tissue evidence of invasive aspergillus. Serum precipitating (IgG) antibodies are present. The treatment includes antifungal agents and surgical resection of the lesion [72].

Saprophytic colonization

Aspergilloma

Aspergilloma or a fungus ball is the most common form of the clinical syndromes caused by aspergillus, but there is little epidemiological data to support the assertion. All species of aspergillus including A. fumigatus and A. niger may colonize old stable pulmonary cavities, bullae or cysts. Patients who develop aspergillomas are usually nonatopic and have chronic underlying lung diseases that include advanced (Stage IV) sarcoidosis, fibrocystic tuberculosis, histoplasmosis, bronchiectasis, interstitial fibrosis or emphysema. The most common primary lung disease that predisposes to aspergilloma is an open healed tuberculous cavity. The interval between the diagnosis of pulmonary tuberculosis and development of the aspergilloma may vary from 1 to 30 yrs. Although aspergillomas, when discovered, may be asymptomatic and benign in appearance, they have the potential to cause life-threatening haemoptysis. Approximately 75–90% of the patients have haemoptysis; most have minor, insignificant bleeding but approximately one quarter of these patients may experience massive haemoptysis. The cause of haemoptysis is erosion of a bronchial artery. Neither the size of the lesion nor associated clinical features predict the development of life-threatening haemoptysis.

The diagnosis of aspergilloma is based on the characteristic radiographic findings in the chest of a moveable, homogeneous opacity inside a cavity. The opacity is usually surrounded by a "halo" or an air-crescent. The necrotic mass of matted hyphae, inflammatory cells, fibrin, and blood which usually lies free within the cavity is aptly termed a fungus ball. Although CT scanning dramatically outlines the crescentic radiolucency surrounding the mass, chest radiographs including posteroanterior and decubitus films are all that are required to establish the diagnosis. The aspergillomas are mostly located in the upper lobes; however, other parts of the lung may also be involved. The lesion may be single or multiple and may show calcification. Adjacent pleura are often thickened; this thickening may precede the development of the fungus ball by months to years (figs. 5 and 6).

Serum precipitating antibodies (IgG) are almost always present, initially in high concentrations, but become weaker, and even negative, if the fungus ball is taken out. Spontaneous resolution of an aspergilloma may occur [73].

Treatment of aspergillomas remains frustrating [74, 75]. Medical therapy has a limited role. Except in rare instances, antifungal drugs (whether given orally, intravenously, by inhalation, or by direct instillation into the cavity) have not been consistently effective [76–78]. Amphotericin-B is highly toxic, itraconazole has not been studied via an intrabronchial catheter. Antifungal agents so far have included amphotericin-B, miconazole, N-acetylcysteine, natamycin, nystatin, sodium iodide, and ampicillin [79].

RUMBAK and KOHLER [80] treated 11 patients with 12 episodes of massive haemoptysis (>600 mL blood·24 h−1). These patients had advanced lung disease and were...
unsuitable for pulmonary resection (FEV₁ <50% predicted). Haemoptysis stopped within 72 h of intracavitary instillation of potassium or sodium iodide with or without amphotericin-B (fig. 6). The treatment did not result in major side-effects. Although bleeding stopped in all patients, resolution of chest radiograph occurred in only three patients. No patients died of haemoptysis, but five of nine patients for whom follow-up was available died of respiratory failure within 4 yrs. In another study YAMADA et al. [81] used amphotericin-B or flucanazole for intracavitary instillation in 12 patients, four of whom had significant haemoptysis. Radiographic resolution occurred in only two patients, whereas, clinical improvement was evident in 10 patients. These are not prospective, double-blind studies. At the present time data are few and do not strongly recommend intracavitary instillation of antifungal agents as a routine therapeutic procedure for every patient with aspergilloma [82]. Furthermore, intracavitary instillation is not a simple procedure. A trained radiologist or a pulmonary specialist is required to perform the procedure.

Bronchial artery embolization should be considered in a patient who is not an ideal candidate for surgery and has not responded to systemic or intracavitary antifungal drugs [83]. The procedure is often unsatisfactory because of the difficulty in identifying the bleeding vessel. Furthermore, even, if an attempt to embolize the vessel succeeds, the bleeding may not stop because of the massive collateral circulation seen so frequently in advanced disease. In one of my patients with advanced sarcoidosis, four attempts at embolization failed to stop haemoptysis. The patient finally died of respiratory failure due to extensive fibrosis. Furthermore, it is not possible to eliminate the fungus ball by embolization.

Surgery offers many clear benefits: the aspergilloma is removed; haemoptysis is controlled; clinical symptoms are abated; quality of life is improved; and finally, life is prolonged. However, surgical resection is a high-risk procedure, particularly in patients with chronic, advanced space, and marked mediastinal adhesions. In such patients mortality may be >25% and the incidence of complications related to haemorrhage, bronchopleural fistula, and empyema approaches 60% [76, 84].

Recently, CIES et al. [76] have reported their experience with 67 patients with aspergilloma treated surgically over a 27-yr period. This is the largest series of surgical resection for aspergilloma. Haemoptysis was present in 61 (91.0%) patients. Tuberculosis was the most common pre-existing illness. Systemic antifungal therapy and intra-arterial embolization were unsuccessful in controlling symptoms and eradicating the disease. Most patients (61.4%) underwent lobectomy. There was one death from pneumonia following surgery. Fifteen postoperative complications in 12 patients included: empyema (7); massive bleeding (3); bronchopleural fistula (2); wound infection (2); and Horner’s syndrome (1). Postoperatively, most of the patients were symptom free. These results clearly show that with advanced planning, appropriate pre-operative management, and judicious surgical technique, surgery is the preferred treatment for pulmonary aspergilloma. The authors recommend early surgery in all patients with good lung function.

Fig. 5. – Posteroanterior view of the chest showing a typical fungus ball (arrow) in the right upper lobe in a patient with advanced sarcoidosis. Note the adjacent pleural thickening commonly seen in patients with fungus ball.

Fig. 6. – Aspergilloma: a) posteroanterior view of the chest showing an egg-shaped fungus ball in the right upper lobe; and b) intracavitary instillation of amphotericin-B caused dissolution of the fungus ball.
before life-threatening haemoptysis or severe pulmonary damage related to the primary disease increases the mortality and morbidity of the operation.

Similar conclusions have been reached by El Oakley et al. [85] from the Royal Brompton Hospital, London. They categorized their 27 consecutive patients referred for surgical assessment, over a period of 14 yrs, into four groups: Class I (n=1), fit individual with mild or no symptoms; Class II (n=17), fit individuals with severe symptoms; Class III (n=1), unfit individuals with no symptoms; and Class IV (n=8), unfit individuals with severe symptoms. Lung resection was performed in all 17 patients with Class II disease, comprising segmentectomy in five patients, lobectomy and segmentectomy in seven, and a complete pneumonectomy in five patients. Cavernoectomy was performed in seven patients with Class IV disease. There were no operative deaths in patients treated by resection, but two of those who underwent cavernoectomy died in the early postoperative period. Surgery was complicated by prolonged air leaks and empyema. Their results clearly stress the importance of good surgical technique to reduce both air leaks and postoperative haemorrhage, and the use thoracoplasty to obliterate the residual pleural space.

Currently, surgical resection is the only logical therapy for aspergilloma. Resection should be planned and performed early before the appearance of a massive fatal haemoptysis or progression of the primary pulmonary disease to such an advanced fibrotic stage making the patient unfit for surgery [86].

**Pulmonary mycotoxicosis**

This is primarily a disease of agricultural animals. Inhalation of an overwhelming amount of aspergillus spores may cause chemical pneumonitis. The clinical picture is acute in onset and characterized by fever, dyspnoea, chest tightness and cyanosis. Chest radiographs show diffuse ground glass haziness and nodular infiltrate. The histological picture consists of a mainly cellular infiltrate of polymorphs, lymphocytes, and plasma cells. The response to corticosteroids is excellent.

**References**


